A new $500 million licensing giant; Covid-19 stalls key China patent case; Lawyers feel PTAB slump; Amgen’s big biosimilars win; NPE sues Uber with ex-IBM IP; plus much more

A new $500 million licensing giant; Covid-19 stalls key China patent case; Lawyers feel PTAB slump; Amgen’s big biosimilars win; NPE sues Uber with ex-IBM IP; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

MONDAY 17th February

Taiwanese company CyWee has been “basically bankrupted by some of the largest companies in the world”, according to its counsel in an IPR case. Read more here

Understanding three significant CAFC rulings could make the difference between success and failure when seeking diagnostic medical claims patents in the US. Read more here

An NPE based in Ireland is acquiring more patents while also launching infringement suits against a string of big-name tech companies. Read more here

TUESDAY 18th February

A patent dispute over biometrics continues to ensnare two companies backed by China’s big government chip fund. Read more here

The UK Supreme Court is set to decide a case over Regeneron transgenic mice patents that will affect how life sciences innovators seek protection for their increasingly complex inventions. Read more here

Fish & Richardson and Sterne Kessler still lead among law firms in PTAB cases, but both saw big reductions in the number of IPRs they handled in 2019. Read more here

WEDNESDAY 19th February

InterDigital faces an onslaught of Huawei-launched invalidity actions at China's patent office, with about half of the decisions still to come. Read more here

Collaboration to develop new products is becoming a new business imperative, according to latest top 100 global innovators report – and that has major IP implications. Read more here 

THURSDAY 20th February

India approves memorandum of understanding with US on IP ahead of Trump visit, but it may not address the reforms multinationals are hoping for. Read more here

Delaware district court sides with Amgen against Genentech in first – and closely watched - cancer biosimilar suit. Read more here

Two critical inventorship issues must be addressed before AI patents in autonomous driving become more commonplace. Read more here

Patents sold-off by IBM in months before joining LOTNet used by NPE to target LOTNet member Uber in new West Texas infringement suit. Read more here

FRIDAY 21st February

The Covid-19 outbreak means that a key appeal in a high-profile, long-running Chinese dispute over internet patents has been put on hold. Read more here

Canadian tech darling Shopify is finally creating a meaningful patent portfolio on the back of a surging market capitalisation, but it still lags rivals – actual and potential. Read more here

TiVo and Xperi edge towards merger and the creation of a $500 million licensing giant, but key questions remain unanswered. Read more here

SATURDAY 22nd February

In order to bring more long-term consistency to US innovation policy, it’s time to rethink how USPTO directors are appointed. Read more here

IAM Benchmarking Survey

IAM’s annual IP benchmarking survey is now underway. We invite you to have your say on the key threats and opportunities facing the IP marketplace by filling in one of our 10-minute questionnaires.

  • If you are a private practice lawyer or attorney, please click here.
  • If you work for an IP-owning company, please click here.

Responses will be accepted until Thursday, 31st March.

Unlock unlimited access to all IAM content